AbbVie Analysis: $363B Raised
What is AbbVie?
Innovative pharmaceuticals enhancing patient lives
Employees
10001+
Founded
2012
Valuation
$362.98 billion
HQ Full Address
1 N Waukegan Rd, North Chicago, Illinois 60064, United States
Revenue Growth Rate
-6.44%
Product Features & Capabilities
- Immunology treatments targeting autoimmune diseases
- Oncology solutions for various cancer types
- Neuroscience therapies addressing mental health conditions
- Eye care products enhancing vision
- Aesthetic solutions for cosmetic needs.
Investment Focus
AbbVie primarily focuses on several therapeutic areas, including Immunology, Oncology, Neuroscience, Eye Care, and Aesthetics. Additionally, they have interests in other specialty areas such as virology and chronic progressive diseases.
Other Considerations
Recognized for diversity and inclusion in the workplace; Operates in over 175 countries; 75% of medicines are first-in-kind.
Key Innovations
- Humira (adalimumab) - Once the world's top-selling drug, Humira is used to treat various autoimmune diseases.
- Imbruvica (ibrutinib) - A treatment for certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
- Venclexta (venetoclax) - Another drug for treating CLL, it works by inducing cancer cell death.
- Skyrizi (risankizumab) - A monoclonal antibody for the treatment of moderate to severe plaque psoriasis and Crohn's disease.
- Rinvoq (upadacitinib) - An oral medication for rheumatoid arthritis and other inflammatory conditions.
- Innovations in Oncology - AbbVie has been focusing on developing new therapies for various cancers, including pipeline products that are currently in clinical trials.
- Investment in Research Facilities - AbbVie has committed significant resources to enhance its R&D capabilities, including a new facility in Germany aimed at expanding its drug discovery efforts. AbbVie is also investing in areas like precision medicine, genetics, and genomics, which are crucial for future biotech innovations.
Awards Recognition
AbbVie has received several awards and recognitions in the biotech field, including being named "Biopharma Company of the Year" at the 2021 Irish Pharma Industry Awards. Additionally, AbbVie won the "Sustainability Initiative of the Year" at the same event and was a runner-up for the overall "Pharma Industry Company of the Year" category.
Latest Funding Round
AbbVie recently engaged in a funding round related to a partnership with EvolveImmune, which started at $65 million. This information was reported approximately five months ago. Additionally, the AbbVie Foundation made a $75 million donation to the University of Chicago Medicine for a new cancer center, also reported five months ago. However, there are no more recent funding rounds found in the latest searches.
Regulatory Approvals
- VYALEV™ (foscarbidopa and foslevodopa) - Approved by the FDA on October 17, 2024, as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults living with advanced Parkinson's disease. - [Source](https://news.abbvie.com/2024-10-17-U-S-FDA-Approves-VYALEV-TM-foscarbidopa-and-foslevodopa-for-Adults-Living-with-Advanced-Parkinsons-Disease)
- EMBLAVEO™ (aztreonam and avibactam) - Approved by the FDA on February 7, 2025, as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic for treating complicated intra-abdominal infections. - [Source](https://news.abbvie.com/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options)
- SKYRIZI® (risankizumab-rzaa) - Approved for the treatment of moderately to severely active ulcerative colitis on June 18, 2024. - [Source](https://news.abbvie.com/2024-06-18-U-S-FDA-Approves-SKYRIZI-R-risankizumab-rzaa-for-Ulcerative-Colitis,-Expanding-AbbVies-Portfolio-Across-Inflammatory-Bowel-Disease)
Partnerships
- Xilio Therapeutics - AbbVie signed a collaboration and option agreement to develop novel tumor-activated immunotherapies, with an upfront payment of $52 million. - [Source](https://www.globenewswire.com/news-release/2025/02/12/3024949/0/en/AbbVie-and-Xilio-Therapeutics-Announce-Collaboration-and-Option-Agreement-to-Develop-Novel-Tumor-Activated-Immunotherapies.html)
- EvolveImmune Therapeutics - A strategic collaboration aimed at advancing next-generation cancer immunotherapy therapies. - [Source](https://thehealthcaretechnologyreport.com/abbvie-and-evolveimmune-partner-to-advance-next-gen-cancer-immunotherapy/)
- Capsida Biotherapeutics - AbbVie exercised a $40 million option to advance a partnered CNS gene therapy. - [Source](https://www.fiercebiotech.com/biotech/abbvie-exercises-first-40-million-option-advance-capsida-partnered-cns-gene-therapy)
- Tentarix Biotherapeutics - A multi-year collaboration focused on developing conditionally-active, multi-specific biologics for oncology and immunology. - [Source](https://www.prnewswire.com/news-releases/abbvie-and-tentarix-announce-collaboration-to-develop-conditionally-active-multi-specific-biologics-for-oncology-and-immunology-302068091.html)
- Anima Biotech - A collaboration worth up to $582 million to discover and develop mRNA modulators. - [Source](https://www.biospace.com/abbvie-anima-strike-mrna-deal-worth-up-to-582)
- Genmab - A broad collaboration agreement to jointly develop and commercialize investigational bispecific antibodies. - [Source](https://ir.genmab.com/news-releases/news-release-details/genmab-and-abbvie-announce-broad-oncology-collaboration)
Find more companies like AbbVie
Financial Overview
$363BTotal Raised
AbbVie recently engaged in a funding round related to a partnership with EvolveImmune, which started at $65 million. This information was reported approximately five months ago. Additionally, the AbbVie Foundation made a $75 million donation to the University of Chicago Medicine for a new cancer center, also reported five months ago. However, there are no more recent funding rounds found in the latest searches.
